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SUMMARY
Glioma-initiating cells (GICs) are responsible for the initiation and recurrence of gliomas. Here, we identify
a molecular mechanism that regulates the self-renewal capacity of patient-derived GICs. We show that
TGF-b and LIF induce the self-renewal capacity and prevent the differentiation of GICs. TGF-b induces the
self-renewal capacity of GICs, but not of normal human neuroprogenitors, through the Smad-dependent
induction of LIF and the subsequent activation of the JAK-STAT pathway. The effect of TGF-b and LIF on
GICs promotes oncogenesis in vivo. Some human gliomas express high levels of LIF that correlate with
high expression of TGF-b2 and neuroprogenitor cell markers. Our results show that TGF-b and LIF have
an essential role in the regulation of GICs in human glioblastoma.INTRODUCTION
Glioma is the most frequent primary tumor of the brain and can
be classified into four clinical grades on the basis of its histology
and prognosis. Grade IV gliomas (glioblastoma multiforme,
GBM) are highly malignant and usually refractory to radio- and
chemotherapy. Despite progress in the understanding of the
molecular mechanisms involved in the genesis and progression
of glioma, prognosis and treatment of this tumor type continue to
be dismal (Furnari et al., 2007; Holland, 2001; Maher et al., 2001;
Zhu and Parada, 2002). Recently, a subpopulation of tumor
cells with stem cell-like properties has been identified in gliomas.
This cell population, called cancer stem cells, glioma stem cells,
brain tumor-initiating cells, or glioma-initiating cells (GICs), is
considered to be responsible for the initiation, propagation,and recurrence of tumors, indicating that more effective thera-
pies will result from approaches aimed at targeting the stem
cell-like compartment of gliomas (Lee et al., 2006; Rich, 2007;
Sanai et al., 2005; Singh et al., 2004a; Stiles and Rowitch,
2008; Vescovi et al., 2006). Still, little is understood regarding
the molecular characteristics and regulatory mechanisms that
control GIC biology.
GICs are characterized by their highly oncogenic potential,
generating tumors that reproduce the characteristics of the
original tumor, their self-renewal capacity, their multilineage
differentiation properties, and their ability to generate detached
spherical cellular structures (neurospheres) when cultured in
serum-free medium. Several markers, most of them previously
described for neuroprogenitor cells, have been reported to iden-
tify GICs. Specifically, a subpopulation of cells in human gliomaSIGNIFICANCE
A defined cell population within the tumor mass, called glioma-initiating cells (GICs), is responsible for glioma initiation
and recurrence and is a critical therapeutic target. The understanding of the molecular mechanisms involved in the
regulation of this type of cell is crucial in order to be able to improve on treatments against glioma. We have identified
TGF-b and LIF, which are highly expressed in malignant glioma, as regulators of the self-renewal capacity of patient-derived
GICs. TGF-b increases GIC self-renewal through the induction of LIF and the JAK-STAT pathway. The induction of GIC self-
renewal by TGF-b and LIF promotes oncogenesis. Our work identifies LIF as a therapeutic target against GICs and provides
a molecular mechanism through which anti-TGF-b therapies might be successful against glioma.Cancer Cell 15, 315–327, April 7, 2009 ª2009 Elsevier Inc. 315
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The TGF-b-LIF Axis Increases GIC Self-Renewaltumors expressing the cell surface protein CD133 (prominin-1)
has been described to be enriched for GICs (Bao et al., 2006;
Galli et al., 2004; Piccirillo et al., 2006; Singh et al., 2003, 2004b).
However, some gliomas contain CD133-negative cells that have
the characteristics of GICs (Beier et al., 2007), indicating that
more refined markers to identify GICs are still needed.
Leukemia inhibitory factor (LIF) is a cytokine that has been
extensively studied as an inducer of mouse embryonic stem
cell self-renewal (Niwa et al., 1998; Williams et al., 1988). More-
over, although LIF can induce astrocytic differentiation in late-
stage mouse neuroprogenitors (Bonni et al., 1997; Rajan and
McKay, 1998), LIF also promotes the self-renewal capacity of
human and mouse early neuroprogenitor cells (Bauer and Patter-
son, 2006; Molne et al., 2000; Wright et al., 2003). Interestingly,
some investigators add recombinant LIF to neural stem cell
culture media to improve the culture yield of neuroprogenitor
cells and GICs (Beier et al., 2007; Carpenter et al., 1999;
Hemmati et al., 2003; Singh et al., 2003; Yuan et al., 2004). LIF
signals through the heterodimeric glycoprotein 130 (gp130)/LIF
receptor (LIFR) complex activating the JAK-STAT pathway
(Auernhammer and Melmed, 2000; Taga and Kishimoto, 1997).
TGF-b family members have been reported to be involved in
embryonic stem cell self-renewal (James et al., 2005; Moses
and Serra, 1996; Xu et al., 2008). TGF-b is a pleiotropic cytokine
that binds and activates a membrane receptor serine/threonine
kinase complex. Upon TGF-b binding, the receptor complex
phosphorylates the transcription factors Smad2 and Smad3,
which then bind to Smad4 and accumulate in the nucleus, where
they regulate transcription (Massague´ et al., 2005; Schmierer
and Hill, 2007; ten Dijke and Hill, 2004). TGF-b has a dual role
in oncogenesis. It is a strong inhibitor of proliferation of normal
epithelial cells and astrocytes and is considered a tumor
suppressor factor. On the other hand, in some tumor types,
and specifically in high-grade glioma, TGF-b becomes an onco-
genic factor (Massague´, 2008; Roberts and Wakefield, 2003;
Seoane, 2006) and is considered a therapeutic target (Akhurst,
2006; Arteaga, 2006; Seoane, 2008; Yingling et al., 2004). Recent
work is beginning to uncover the oncogenic function of TGF-b
in glioma (Rich, 2003). We found that TGF-b is highly active in
high-grade glioma and that elevated TGF-b activity confers
poor prognosis in glioma patients. TGF-b induces cell prolifera-
tion and tumor progression through the induction of PDGF-B
in human gliomas with an unmethylated PDGF-B gene (Bruna
et al., 2007).
In this study, we aimed to understand the molecular mecha-
nisms underlying the effect of the TGF-b pathway on the regula-
tion of GIC self-renewal.
RESULTS
TGF-b Induces Patient-Derived GIC Self-Renewal
In order to study the effect of TGF-b on the self-renewal capacity
of GICs, we obtained cells from surgically resected human GBM
samples (see Table S1 available online). From each tumor
specimen, we generated primary cultures of tumor cells (PCTCs)
in the presence of serum and, in parallel, cultured tumor cells in
serum-free medium in the presence of epidermal growth factor
(EGF) and fibroblast growth factor (FGF). Cells cultured in
the EGF- and FGF-supplemented serum-free medium readily316 Cancer Cell 15, 315–327, April 7, 2009 ª2009 Elsevier Inc.generated nonadherent, multicellular spheres (neurospheres)
as described previously (Galli et al., 2004; Gu¨nther et al., 2007;
Lee et al., 2006; Singh et al., 2003) (Figure 1A). Neurospheres
originating from the tumor specimens expressed high levels of
the neuroprogenitor cell markers Musashi-1, Sox2, and nestin
(Figure 1B) and underwent multilineage differentiation acquiring
the expression of GFAP (astrocytic marker), Tuj1 (neuronal
marker), and O4 (oligodendrocytic marker) when cultured in
the presence of serum (Figure S1). Moreover, tumor-derived
neurospheres were highly oncogenic as compared to PCTCs.
We performed in vivo limiting dilution assays implanting
decreasing amounts of cells from neurospheres and from PCTCs
in the brains of immunocompromised mice. Tumor growth was
assessed by magnetic resonance imaging (MRI). Neurosphere
cells generated invasive and infiltrative tumors detectable by
MRI. In contrast, mice injected with 1 3 105 PCTCs did not
develop tumors during the studied time frame (Figure 1C).
Tumors generated in mice were confirmed to have histopatho-
logical characteristics of GBM and had the same levels and
expression pattern of neuroprogenitor markers (Musashi-1,
Sox2, and nestin) as the original tumors (Figure S2). Thus, neuro-
spheres generated from human GBM specimens expressed
neuroprogenitor cell markers, showed multilineage differentia-
tion potential, and were highly oncogenic, generating tumors
with the same characteristics as the original human tumors. All
of these properties indicated that neurospheres obtained from
patient-derived GBMs are enriched for GICs.
We decided to assess the effect of TGF-b on GIC self-renewal
following a well-described protocol based on the ability of GICs
to generate neurospheres (Reynolds and Weiss, 1996; Seaberg
and van der Kooy, 2002). Patient-derived neurospheres from
three different glioma patients were dissociated into single cells
and treated with TGF-b or left untreated for 7 days in the absence
of growth factors, and the newly formed neurospheres and
the total number of cells were then counted. Treatment with
TGF-b enhanced the number of neurospheres and increased the
total number of cells. The effect of TGF-b was blocked when
a TGF-b receptor I (TbRI) inhibitor was added concomitantly
with TGF-b (Figures 1D–1F). Moreover, there was a dose-depen-
dent effect of TGF-b on the number of neurospheres and cells,
and the effect of TGF-b on self-renewal was observed even
when cells were plated at very low density (Figure S3). These
results showed that the TGF-b pathway increases GIC self-
renewal.
TGF-b Induces LIF Expression in Human GBM Cells
We decided to discern the molecular mechanisms responsible
for the effect of TGF-b on GICs. We looked for TGF-b gene
responses in GBM cells that could be involved in the regulation
of GIC self-renewal. In our previous work (Bruna et al., 2007),
we performed a transcriptomic analysis of the U373MG glioma
cell line treated with TGF-b and/or a TbRI inhibitor. LIF was
among the 63 TGF-b gene responses in U373MG cells that
were dependent on TbRI activity. The LIF-LIFR/gp130-JAK-
STAT signaling pathway has been implicated in stem cell self-
renewal in both embryonic stem cells (Niwa et al., 1998; Williams
et al., 1988) and neuroprogenitor cells (Bauer and Patterson,
2006; Molne et al., 2000; Wright et al., 2003), and we hypothe-
sized that LIF could be involved in GIC self-renewal and
Cancer Cell
The TGF-b-LIF Axis Increases GIC Self-RenewalFigure 1. Effect of TGF-b on Patient-Derived Glioma-Initiating Cell Self-Renewal
(A) Representative images of primary cultures of tumor cells (PCTCs) and glioblastoma multiforme (GBM) neurospheres generated from specimens of three
different GBM patients. Scale bar = 300 mm.
(B) Musashi-1 (Msi-1), Sox2, Nestin, and b-actin levels were determined by RT-PCR analysis of PCTCs and neurospheres from three human GBM samples.
(C) Representative MRI images of brains of immunocompromised mice inoculated with 1 3 105 PCTCs or 1000 neurosphere cells from GBM1.
(D and E) Cells from the indicated GBM neurospheres were incubated in the absence of growth factors with 100 pM TGF-b1 and/or 2 mM TbRI inhibitor (TbRI inh)
for 7 days, and the percentage of neurosphere-forming cells (D) and the total number of cells (E) were determined. *p < 0.05; **p < 0.005.
(F) Representative images of GBM1 neurospheres treated as indicated in (D and E). Scale bar = 400 mm.
(G) PCTCs from 11 human GBM samples (GBM1–11) were treated with 100 pM TGF-b1 or left untreated for 3 hr, and the levels of LIF expression were determined
by qRT-PCR. b-actin was used as an internal normalization control.
(H) Cells from GBM neurospheres were treated with 100 pM TGF-b1 or left untreated for 3 hr, and the levels of LIF expression were determined by qRT-PCR.
(I) Secreted LIF protein levels were determined by ELISA in GBM1 neurospheres after 48 hr treatment with 100 pM TGF-b1.
Error bars represent mean ± standard deviation (SD).mediating the effect of TGF-b on GICs. We first determined
whether the TGF-b-mediated induction of the LIF transcript
was observed in patient-derived tumor cells. A panel of PCTCs
derived from 11 different human GBMs was treated with TGF-b for
3 hr, and LIF mRNA levels were determined. TGF-b induced
LIF in all PCTCs assayed (Figure 1G). These results indicated
that the induction of LIF by TGF-b is a common phenomenon
that takes place in most human GBMs. In order to assess the
effect of LIF on PCTCs, we treated PCTCs from GBMs 1, 2,
and 3 with LIF. Cell proliferation was not affected by treatment
with LIF either when cells were counted after 7 days of treatment
or by BrdU incorporation assays (Figure S4). In patient-derived
neurospheres, TGF-b was able to induce the LIF transcript
(Figure 1H), and this effect was dependent on TbRI activity since
LIF induction by TGF-bwas blocked by the presence of a TbRI in-
hibitor (Figure S5). Three members of the TGF-b family (TGF-b1,TGF-b2, and TGF-b3) were able to induce LIF in patient-derived
neurospheres (Figure S5), and, as expected, the induction of the
LIF transcript by TGF-b resulted in an increase in LIF protein
secretion as measured by ELISA in neurosphere-conditioned
medium (Figure 1I).
TGF-b Induces LIF Expression via an Activated Smad
Complex Binding to the LIF Promoter
To study the transcriptional regulation of LIFby TGF-b, we cloned
the human LIF promoter into the pGL2 basic reporter construct.
TGF-b was able to transactivate reporter constructs containing
the 634/+32 and 276/+32 regions of the LIF promoter. The
73/+32 fragment of the LIF promoter lost the transcriptional
response to TGF-b, indicating that the TGF-b-responsive
element was included in the 276/73 region (Figures 2A and
2B). This region contains a single Smad-binding element (SBE,Cancer Cell 15, 315–327, April 7, 2009 ª2009 Elsevier Inc. 317
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The TGF-b-LIF Axis Increases GIC Self-RenewalFigure 2. TGF-b Induces LIF Transcription through an Activated Smad Complex
(A) Scheme of LIF luciferase reporter constructs.
(B) A172 glioma cells were transfected with the 634/+32, 276/+32, or 276/+32 mutated Smad-binding element (mutSBE) or 73/+32 LIF luciferase reporter
constructs. Cells were then treated with 100 pM TGF-b1 for 20 hr, and luciferase activity was analyzed.
(C) U373MG cells were treated with 100 pM TGF-b1 for 3 hr, and chromatin immunoprecipitation (ChIP) assays were performed with the indicated antibodies
and the indicated PCR primers.
(D and E) LIF mRNA levels were determined by qRT-PCR in U373MG cells (D) or GBM1 neurospheres (E) treated with 100 pM TGF-b1 for 3 hr after siRNA-
mediated knockdown of the indicated Smad family members. Immunoblotting was performed with the indicated antibodies against Smads.
Error bars represent mean ± SD.50-GTCT-30) close to an SP1 binding site (Figure 2A). We
mutated the SBE and observed that the response to TGF-
b was blunted (Figure 2B), indicating that an activated Smad
complex binds to the proximal SBE in the LIF promoter to induce
transcription. We performed chromatin immunoprecipitation
(ChIP) assays and observed that endogenous Smad2 bound
to the proximal region of the LIF promoter and not to a distal
region 4 kb upstream of the transcription start site in TGF-
b-treated cells (Figure 2C). Finally, to prove that Smads are
involved in the induction of LIF expression by TGF-b, we
knocked down Smad2, Smad3, both Smad2 and 3, and Smad4
using two independent siRNAs against each of the Smads. LIF
induction by TGF-b was decreased when Smad4 or both
Smad2 and Smad3 were downregulated, indicating that an acti-
vated Smad complex is required for the LIF transcriptional
response to TGF-b (Figure 2D; Figure S6). Smad2 and Smad3
are redundant in this process since knockdown of each Smad
in isolation did not significantly affect TGF-b-induced LIF levels
(Figure 2D; Figure S6). As expected, the induction of LIF by
TGF-b in patient-derived neurospheres was also Smad depen-
dent. Knockdown of Smad4 with two independent siRNAs in318 Cancer Cell 15, 315–327, April 7, 2009 ª2009 Elsevier Inc.human GBM neurospheres abolished the LIF response to
TGF-b (Figure 2E).
TGF-b Induces the JAK-STAT Pathway through
the Induction of LIF in Patient-Derived Neurospheres
In order to discern whether the LIF signaling pathway is functional
in GBM neurospheres, we treated the neurospheres with
recombinant LIF and determined the phosphorylation levels of
the downstream substrate of the LIF receptor complex, STAT3.
Recombinant LIF induced a rapid phosphorylation of STAT3
at Tyr705 and did not increase the phosphorylation of STAT3 at
Ser727. The latter residue was already phosphorylated
in untreated cells (Figure S7). Moreover, the induction of
p-STAT3 at Tyr705 (hereafter, p-STAT3) by LIF was prevented
by the presence of a specific pharmacological inhibitor of JAK,
tetracyclic pyridone 6 (P6) (Pedranzini et al., 2006; Thompson
et al., 2002) (Figure 3A). Importantly, TGF-b induced STAT3
phosphorylation in GBM neurospheres, and the TbRI inhibitor
prevented that effect (Figure 3B). We decided to assess whether
LIF was mediating the induction of p-STAT3 by TGF-b. For this
purpose, we used a neutralizing antibody against LIF to
Cancer Cell
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cells. The presence of the LIF-neutralizing antibody decreased
the induction of p-STAT3 by TGF-b. Moreover, we observed
that the induction of p-STAT3 by TGF-b was dependent on JAK
activity since p-STAT3 levels in TGF-b-treated cells were
repressed by treatment with the JAK inhibitor P6 (Figure 3C).
Additionally, we decided to knock down LIF expression using
RNA interference in order to confirm that LIF was mediating the
induction of p-STAT3 by TGF-b. GBM neurospheres were trans-
fected with two independent siRNAs against LIF, and the induc-
Figure 3. TGF-b Induces the LIF-JAK-STAT Pathway in Patient-
Derived GBM Neurospheres
(A) GBM1 neurospheres were treated with 20 ng/ml LIF and/or 0.5 mM P6
(a specific pharmacological inhibitor of JAK) for 15 min, and the levels of
p-STAT3 and STAT3 were determined by immunoblotting.
(B) GBM1 neurospheres were treated with 100 pM TGF-b1 and/or 2 mM TbRI
inhibitor for 4 hr in the absence of EGF and FGF, and levels of p-STAT3, STAT3,
p-Smad2, Smad2, and a-tubulin were determined by immunoblotting.
(C) GBM1 neurospheres were treated with 100 pM TGF-b1, 0.5 mM P6, or
10 mg/ml anti-LIF neutralizing antibody for 4 hr as in (B), and the levels of
p-STAT3, STAT3, p-Smad2, Smad2, and a-tubulin were determined by
immunoblotting.
(D) GBM1 neurospheres were transfected with two independent siRNAs
against LIF and treated with 100 pM TGF-b1 or left untreated for 4 hr.
p-STAT3, STAT3, and p-Smad2 levels were determined by immunoblotting.
qRT-PCR analysis was performed to determine LIF levels, with b-actin used
as an internal normalization control. Error bars represent mean ± SD.tion of p-STAT3 by TGF-bwas observed to decrease (Figure 3D).
Altogether, these results indicated that TGF-b activates the JAK-
STAT pathway in patient-derived neurospheres via the induction
of LIF secretion acting through an autocrine/paracrine loop.
LIF Mediates the Induction of GIC Self-Renewal
by TGF-b
We decided to evaluate whether LIF and the JAK-STAT pathway
mediate the increase of GIC self-renewal by TGF-b. For this
purpose, we used LIF-neutralizing antibodies, the pharmacolog-
ical JAK inhibitor P6, and siRNAs against LIF to specifically block
the effect of secreted LIF in cells treated with TGF-b.
Neurospheres were dissociated into single cells and treated
with recombinant LIF, TGF-b, anti-LIF antibody, and/or P6. The
newly formed neurospheres and the total number of cells were
counted. Recombinant LIF increased the amount and size of
the newly formed neurospheres as well as the total number of
cells, indicating that LIF induces GIC self-renewal (Figures 4A–
4C). Treatment with the LIF-neutralizing antibody decreased
the induction of GIC self-renewal by TGF-b. Moreover, P6 also
repressed the effect of TGF-b on GIC self-renewal, indicating
that the TGF-b effect on self-renewal was dependent on JAK
activity (Figures 4A and 4B). TGF-b and LIF did not affect BrdU
incorporation of treated neurospheres (Figure S8). We next
confirmed that the effect of TGF-b on GIC self-renewal is
mediated by LIF using RNA interference. We observed that
knockdown of LIF using two independent siRNAs previously
shown to block p-STAT3 induction by TGF-b (see Figure 3D) also
prevented the induction of GIC self-renewal by TGF-b (Figure 4D).
We then performed a different type of experiment to assess
GIC self-renewal. Neurospheres were dissociated into single
cells and treated with LIF, TGF-b, anti-LIF, and/or P6 as indi-
cated for 7 days. The newly formed neurospheres were then
dissociated, the same number of isolated cells was plated into
96-well plates in the absence of treatment, and the number of
cells capable of generating neurospheres was determined.
This process was performed for over three passages. Following
this protocol, we observed that TGF-b and LIF increased the
number of neurosphere-forming cells and hence the self-renewal
capacity of GICs, and that the TGF-b effect was dependent on
the induction of LIF and the JAK-STAT pathway (Figure S9).
To further validate the effect of TGF-b and LIF on GIC self-
renewal, we performed soft agar assays. GBM neurospheres
were dissociated, and the same number of cells was treated
with TGF-b or LIF for 7 days. After treatment, dissociated neuro-
spheres were plated in the absence of treatment in soft agar,
and the number of generated colonies was determined. Cells
previously treated with TGF-b or LIF generated an increased
number of colonies in soft agar suspension cultures as
compared to untreated cells (Figure 4E; Figure S10).
Next, we decided to analyze the levels of CD133-positive cells
in the GBM neurospheres. Our three patient-derived neuro-
spheres had a percentage of CD133-positive cells ranging
from 3% to 20% (Figure 4F; Figure S11). Treatment of the neuro-
spheres with TGF-b or LIF for 7 days doubled the percentage of
CD133-positive cells present in GBM1 neurospheres (Figure 4F).
Overall, our data indicate that TGF-b induces the self-renewal
capacity of patient-derived GICs through the LIF-JAK-STAT
pathway.Cancer Cell 15, 315–327, April 7, 2009 ª2009 Elsevier Inc. 319
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The TGF-b-LIF Axis Increases GIC Self-RenewalFigure 4. LIF Mediates the Increase of Glioma-Initiating Cell Self-Renewal by TGF-b
(A and B) Cells from GBM1, GBM2, or GBM3 neurospheres were treated with 100 pM TGF-b1, 20 ng/ml LIF, and/or 10 mg/ml anti-LIF neutralizing antibody
and 0.5 mM P6 in the absence of EGF and FGF, and the number of newly formed neurospheres (A) and the total number of cells (B) were determined.
*p < 0.05; **p < 0.005.
(C) Representative images of GBM1 neurospheres treated as indicated in (A and B). Scale bar = 400 mm. Lower right: the percentage of neurospheres larger than
75 mm was determined.
(D) GBM1 neurospheres were transfected with two independent siRNAs against LIF as in Figure 3D and incubated in the absence of growth factors with 100 pM
TGF-b1 for 7 days, and the percentage of neurosphere-forming cells was determined. **p < 0.005.
(E) Cells from GBM1 neurospheres were treated with 100 pM TGF-b1 or 20 ng/ml LIF for 7 days and plated in soft agar. The number of colonies was determined
after staining with 0.01% crystal violet. **p < 0.005.
(F) The percentage of CD133-positive cells from the indicated GBM neurosphere cultures was determined by flow cytometry. Cells from GBM1 neurospheres
were incubated with 100 pM TGF-b1 or 20 ng/ml LIF for 7 days, and the percentage of CD133-positive cells was determined.
Error bars represent mean ± SD.TGF-b Prevents GIC Differentiation via LIF
GBM-derived neurospheres tend to differentiate either by
culturing in the presence of serum or, alternatively, by culturing
in the absence of growth factors. During the differentiation
process, cells tend to acquire markers of differentiation (GFAP,
S100b, Tuj1, O4, Olig2), lose the expression of neuroprogenitor
markers (Musashi-1, Sox2, nestin), and become attached to
the culture plate, losing the spherical shape. We decided to
assess the effect of TGF-b and LIF on differentiation following
the two mentioned differentiation protocols.
Neurospheres cultured in the presence of serum and TGF-b or
LIF suffered a delay in differentiation. A time-course experiment
showed that cells treated with TGF-b or LIF acquired the markers
of differentiation GFAP, Tuj1, and Olig2 (Figure 5A) and S100b,
Tuj1, and O4 (Figure 5B) later than untreated cells. In addition,
TGF-b- or LIF-treated neurospheres maintained the expression320 Cancer Cell 15, 315–327, April 7, 2009 ª2009 Elsevier Inc.of neuroprogenitor markers (Musashi-1, Sox2, and nestin) and
became less attached to the culture plate, maintaining the
spherical morphology (Figure 5B). Moreover, when neuro-
spheres were induced to differentiate in the absence of EGF
and FGF for 7 days, TGF-b and LIF also retained the expression
of Musashi-1, Sox2, and nestin as detected by immunocyto-
chemical assays and as quantified by qRT-PCR, and the cells
maintained the spherical, detached morphology (Figure S12).
Overall, our results indicated that TGF-b and LIF not only regu-
late GIC self-renewal but also prevent the differentiation of GICs.
Effect of TGF-b and LIF on Normal Human
Neuroprogenitors
Our data indicated that TGF-b and LIF regulate GIC self-renewal
and differentiation. Still, we wanted to address whether this
effect is specific to tumor cells or is also present in normal
Cancer Cell
The TGF-b-LIF Axis Increases GIC Self-RenewalFigure 5. TGF-b and LIF Prevent Differentiation of GBM Neurospheres
(A) qRT-PCR analysis was performed to determine the mRNA levels of the differentiation markers GFAP, Tuj1, and Olig2 in GBM1 neurospheres after 7 days of
the indicated treatments in the presence of 0.05% FBS. GAPDH mRNA levels were used as an internal normalization control. Error bars represent mean ± SD.
(B) Immunocytochemistry for the indicated proteins was performed in GBM1-derived neurospheres treated with 100 pM TGF-b1 or 20 ng/ml LIF for 7 days
in the presence of 0.05% FBS on poly-L-lysine-coated coverslips. Nuclei were counterstained with DAPI. Scale bar = 300 mm.neuroprogenitor cells. To answer this question, we obtained
neuroprogenitor cells from five different human fetal cerebral
cortex samples (8–16 weeks postconception). As described
previously, human neuroprogenitors generated neurospheres
when grown in serum-free medium supplemented with EGF
and FGF, and these neurospheres expressed Musashi-1,
Sox2, and nestin similarly to GBM neurospheres (Figure 6A).
First, we determined whether TGF-b induced LIF in normal
human neuroprogenitors. Normal neurospheres obtained from
the five human fetal cerebral cortex samples did not induce LIF
in response to TGF-b (TGF-b1, TGF-b2, or TGF-b3) to the
same extent as GBM neurospheres (Figures 6B and 6C). More-
over, TGF-b did not induce LIF in mouse neuroprogenitors
obtained from mouse embryos or from the subventricular zone
of adult mice (data not shown). We analyzed the levels of TbRI,
TbRII, Smad2, Smad3, Smad4, LIFR, and gp130 in GBM PCTCs,
GBM neurospheres, and three of the normal neuroprogenitor
neurosphere samples in order to determine the levels of the
mediators of TGF-b and LIF signaling pathways and to assess
whether the lack of one of the mediators of TGF-b was respon-
sible for the inability of TGF-b to induce LIF. The levels of expres-
sion of the analyzed factors varied among samples, but none
was absent in normal neuroprogenitors (Figure S13). Moreover,TGF-b induced p-Smad2 in normal neuroprogenitors at the same
level as in GBM neurospheres, indicating that the difference
between the two cell types resides downstream of p-Smad2
(Figure 6D). In addition, Smad7 expression, a well-defined
TGF-b response, was induced by TGF-b in both neuroprogeni-
tors and GBM neurospheres (Figure 6B). Thus, the observed
difference between GBM neurospheres and neuroprogenitors
in the LIF response to TGF-b resides downstream of p-Smad2
and is specific to the LIF transcriptional response.
TGF-b did not increase the self-renewal capacity of normal
neuroprogenitors, and the number of neuroprogenitor neuro-
spheres was not increased by treatment with TGF-b (Figure 6E).
LIF, on the other hand, did increase the number and size of newly
formed neurospheres as well as the total number of cells
(Figure 6E), in agreement with previous reports (Bauer and Pat-
terson, 2006; Wright et al., 2003). Thus, LIF has the same effect
on self-renewal in normal and GBM neurospheres. In contrast,
there is a difference in the TGF-b effect on the self-renewal
capacity of normal and tumoral neurospheres that coincides
with the inability of TGF-b to induce LIF in normal neuroprogeni-
tors to the same level as in GBM neurospheres.
Next, we evaluated the effect of TGF-b and LIF on the capacity
of normal human neuroprogenitors to differentiate in response toCancer Cell 15, 315–327, April 7, 2009 ª2009 Elsevier Inc. 321
Cancer Cell
The TGF-b-LIF Axis Increases GIC Self-RenewalFigure 6. TGF-b Effect on the Self-Renewal Capacity of Normal Human Neuroprogenitors
(A) Immunocytochemistry for the indicated neuroprogenitor markers was performed in human neuroprogenitor neurospheres. Nuclei were counterstained
with DAPI. Scale bar = 200 mm.
(B) Neurospheres from GBM1 and from neuroprogenitors isolated from samples of five different fetal cerebral cortices from animals 16 to 8 weeks postconception
(NP1–NP5) were incubated with 100 pM TGF-b1 for 3 hr. LIF and Smad7 mRNA levels were determined by qRT-PCR, with GAPDH used as an internal
normalization control. *p < 0.05; **p < 0.005.
(C) Neurospheres from GBM1 and from normal human neuroprogenitors were incubated with 100 pM concentrations of the indicated TGF-b family members for
3 hr, and LIF mRNA levels were determined.
(D) p-Smad2 and Smad2 levels were determined by immunoblotting in GBM1 neurospheres and NP1 neurospheres after treatment with TGF-b for 3 hr.
(E) NP1 cells were incubated in the absence of growth factors with 100 pM TGF-b1 or 20 ng/ml LIF for 7 days, and the percentage of neurosphere-forming cells
and the total number of cells were determined. **p < 0.005.
Error bars represent mean ± SD.treatment with serum. As in GBM neurospheres, serum induced
the attachment and loss of spherical morphology of neuro-
spheres, decreased the expression of neuroprogenitor markers
(Musashi-1, Sox2, and nestin), and promoted the appearance
of differentiation markers (S100b, Tuj1, and O4) (Figure S14).
LIF delayed the differentiation process of normal neuroprogeni-
tors, maintaining the detached spherical morphology and
expression of neuroprogenitor markers and preventing the
expression of differentiation markers. In contrast, TGF-b did not
have a major effect on the differentiation process (Figure S14).
LIF Expression in Human Gliomas Correlates
with TGF-b2 and Neuroprogenitor Markers
In order to evaluate whether LIF is expressed in human gliomas,
we analyzed the levels of LIF in a panel of 43 glioma samples,
including the samples that originated GBM1 (patient #40),
GBM2 (patient #41), and GBM3 (patient #42) neurospheres.
We observed that LIF was expressed in 20 and highly expressed
in 7 of the 43 gliomas (Figure 7A), indicating that a large322 Cancer Cell 15, 315–327, April 7, 2009 ª2009 Elsevier Inc.proportion of human gliomas express LIF. Since LIF is induced
by TGF-b and since we found in our previous work that
TGF-b2 is mainly responsible for the high TGF-b activity
observed in gliomas (Bruna et al., 2007), we assessed whether
TGF-b2 is implicated in LIF expression. Indeed, LIF levels
correlated with TGF-b2 in our panel of gliomas, further support-
ing that TGF-b2 is responsible for the induction of LIF in human
glioma (Figures 7A and 7B). If LIF promotes GIC self-renewal,
the pool of cells expressing neuroprogenitor markers should
be enriched in tumors expressing high levels of LIF. To address
this hypothesis, we compared the levels of LIF with the expres-
sion of neuroprogenitor markers. LIF levels correlated with the
expression of Musashi-1 and nestin, but not Sox2 (Figures 7A
and 7B). The correlation was mainly based on some gliomas in
which the expression of LIF, TGF-b2, and neuroprogenitor
markers was high, and hence the relationship between LIF and
TGF-b2, Musashi-1, and nestin might not be present in the
majority of tumors. Our data indicate that in certain tumors
with high levels of TGF-b2, LIF promotes GIC self-renewal,
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present in the tumor mass.
TGF-b and LIF Induce the Oncogenic Potential of GBM
Neurospheres
At this point, we decided to address whether the observed effect
of TGF-b and LIF on GIC self-renewal could translate into an
increase in the capacity of GBM neurospheres to initiate tumors.
To address this possibility, we followed three different
approaches. In a first experiment, we treated dissociated GBM
neurospheres with TGF-b or LIF for 14 days. Cells from the newly
formed neurospheres were orthotopically inoculated in the
brain of immunocompromised mice. Neurospheres that were
pretreated with TGF-b or LIF generated tumors earlier than
untreated cells, and mice inoculated with neurospheres
pretreated with TGF-b or LIF exhibited significantly decreased
survival compared to mice inoculated with untreated neuro-
spheres (Figure 8A). Thus, GBM neurospheres previously treated
with TGF-b and LIF were more oncogenic, confirming that they
were enriched in GICs.
Next, we decided to perform a loss-of-function experiment. In
order to detect a physiological effect of the attenuation of the
TGF-b and LIF pathways on GICs, we treated GBM neuro-
spheres cultured at a high density (conditions where the endog-
enous basal TGF-b and JAK pathways are functional due to
autocrine signaling) with TbRI inhibitor and JAK inhibitor.
GBM neurospheres expressed and secreted functional TGF-b
Figure 7. LIF Expression in Human Glioma
Tumors
(A) LIF, TGF-b2, Musashi-1 (Msi-1), Sox2, and
Nestin transcript levels were determined by qRT-
PCR analysis of 43 human glioma patient-derived
tissue samples. 18S RNA levels were used as an
internal normalization control. GBM1, GBM2,
GBM3, and GBM4 in other figures correspond to
patients #40, #41, #42, and #43, respectively.
(B) Correlations between LIF and TGF-b2, Msi-1,
Sox2, or Nestin. Spearman’s rank correlation
coefficient (Rho) with two-tailed significance is
shown.
(Figure S15), and, when cultured at high
density (100 cells/ml), GBM neurospheres
were exposed to autocrine TGF-b
(Figure S15). We also obtained neuro-
spheres from a tumor that expressed
high levels of TGF-b and LIF, GBM4
(patient #43) (see Figure 7). GBM4 neuro-
spheres were as sensitive to TGF-b and
LIF as GBM1, 2, and 3 neurospheres
(Figure S16), and, although they were
generated from a tumor with high levels
of TGF-b and LIF, GBM4 neurospheres
were exposed to a level of autocrine
TGF-b activity similar to the rest of the
GBM neurospheres (Figure S15). In all
cases, treatment of GBM neurospheres
cultured at high density with TbRI inhibitor
and JAK inhibitor repressed the GIC self-renewal capacity
(Figure 8B). Moreover, mice that were intracerebrally inoculated
with GBM4 neurospheres that were previously treated with TbRI
inhibitor and JAK inhibitor exhibited significantly prolonged
survival (Figure 8C). These results indicated that inhibition of the
TGF-b and JAK-STAT pathways decreased the self-renewal and
tumorigenic potential of GICs.
In a third approach, we overexpressed TGF-b, a constitutively
active version of TbRI (TbRI-CA), and LIF in GBM1 neurospheres
through the infection of cells with lentiviral vectors. Lenti-TGF-b-
and lenti-TbRI-CA-infected GBM neurospheres expressed high
levels of TGF-b and TbRI-CA, respectively, and both expressed
high levels of p-Smad2, LIF, and p-STAT3 due to the activation
of the TGF-b pathway (Figure S17). Lenti-LIF-infected GBM
neurospheres expressed LIF and had higher levels of p-STAT3
(Figure S17). As expected, neurospheres overexpressing
TGF-b, TbRI-CA, and LIF had increased self-renewal capacity
compared to control lentivirus-infected cells (Figure 8D). Cells
infected with the indicated lentivirus were inoculated in the brain
of immunocompromised mice, and we performed two types of
experiments. First, the overall survival of mice inoculated with
lentivirus-infected cells was assessed (Figure 8E). Second, the
tumor burden was analyzed and quantified by MRI 40 days after
inoculation (Figures 8F and 8G). Mice inoculated with cells
infected with lentivirus expressing TGF-b, TbRI-CA, or LIF had
significantly shorter overall survival and generated significantly
larger tumors than mice inoculated with control infected cellsCancer Cell 15, 315–327, April 7, 2009 ª2009 Elsevier Inc. 323
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Increase the Oncogenic Potential of GBM
Neurospheres
(A) Cells from GBM1 neurospheres, previously
treated with 100 pM TGF-b1 or 20 ng/ml LIF
for 14 days, were inoculated in the brains of
immunocompromised mice. Animal survival was
evaluated using a log-rank analysis from a Kaplan-
Meier survival curve (p = 0.021 comparing
control and TGF-b; p = 0.002 comparing control
and LIF).
(B) Cells from the indicated GBM neurospheres
plated at 100 cells/ml were treated with TbRI
inhibitor or JAK inhibitor (P6) for 7 days. Neuro-
spheres were then dissociated and plated in the
absence of treatment for 7 days, and the newly
formed neurospheres were counted. *p < 0.05;
**p < 0.005.
(C) Cells from GBM4 neurospheres, previously
treated at 100 cells/ml with 2 mM TbRI inhibitor or
0.5 mM P6 for 14 days, were inoculated in the
brains of immunocompromised mice. Animal
survival was evaluated using a log-rank analysis
from a Kaplan-Meier survival curve (p = 0.032
comparing control and TbRI inhibitor; p = 0.002
comparing control and P6).
(D) Cells from GBM1 neurospheres infected with
the indicated lentiviruses were incubated in the
absence of growth factors for 7 days, and the
percentage of neurosphere-forming cells was
determined.
(E) Cells from GBM1 neurospheres, previously
infected with lenti-control, lenti-TGF-b1, lenti-
TbRI-CA, or lenti-LIF, were inoculated in the brains
of immunocompromised mice. Animal survival
was evaluated using a log-rank analysis from
a Kaplan-Meier survival curve (p < 0.001
comparing lenti-control and lenti-TGF-b1;
p < 0.001 comparing lenti-control and lenti-
TbRI-CA; p < 0.001 comparing lenti-control and
lenti-LIF).
(F and G) Cells from GBM1 neurospheres,
previously infected with lenti-control, lenti-TGF-
b1, lenti-TbRI-CA, or lenti-LIF, were inoculated in
the brains of immunocompromised mice. Forty
days after surgery, images from the entire mouse
brains were obtained by MRI (G), and tumor area was quantified (F). p = 0.0005 comparing lenti-control and lenti-TGF-b1; p = 0.0001 comparing lenti-control
and lenti-TbRI-CA; p = 0.0172 comparing lenti-control and lenti-LIF.
Error bars represent mean ± SD.(Figures 8E–8G). Thus, the TGF-b and LIF pathways enhance the
oncogenic capacity of GBM neurospheres, corroborating their
effect on GIC self-renewal.
DISCUSSION
Recent evidence indicates that GICs are responsible for the
initiation, propagation, recurrence, and therapeutic failures of
gliomas (Bao et al., 2006), and hence GICs are considered to
be critical therapeutic targets (Sanai et al., 2005; Vescovi et al.,
2006). An understanding of the molecular mechanisms involved
in the regulation of GICs is crucial in order to be able to design
efficient therapeutic strategies and to improve on conventional
anticancer treatments, which presently have limited success324 Cancer Cell 15, 315–327, April 7, 2009 ª2009 Elsevier Inc.against glioma. Here, we have identified a molecular pathway
that regulates the self-renewal capacity of GICs.
We and others have implicated the TGF-b pathway in glioma
(Bruna et al., 2007; Rich, 2003). TGF-b is a cytokine with a dual
role in cancer, and while it acts as a tumor suppressor in normal
epithelial cells and early-stage tumors, it becomes an oncogenic
factor in advanced tumors, inducing proliferation, angiogenesis,
invasion, suppression of the immune response, and metastasis
(Roberts and Wakefield, 2003; Siegel and Massague´, 2003).
Specifically in high-grade glioma, the TGF-b pathway acts as
an oncogenic factor (Bruna et al., 2007). A highly active TGF-
b pathway confers poor prognosis in human glioma patients,
and TGF-b acts as a proliferative and oncogenic factor through
the induction of PDGF-B in gliomas with an unmethylated
PDGF-B gene (Bruna et al., 2007). Here, we have identified
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response in human glioma. TGF-b increases the self-renewal
capacity and prevents the differentiation of GICs isolated from
patient-derived glioma specimens. Moreover, we have identified
LIF as a mediator of the TGF-b effects on GICs. TGF-b induces
LIF in most GBMs, and LIF in turn promotes GIC self-renewal,
increasing the GIC population within the tumor mass. We have
observed that the induction of GIC self-renewal by TGF-b and
LIF translates into an increased oncogenic capacity. TGF-bor LIF
treatment enriches GBM neurospheres for GICs and increase
the capacity of neurospheres to generate tumors. In addition,
neurospheres engineered to have highly active TGF-b and LIF
pathways, as observed in certain human gliomas, become
more tumorigenic.
LIF is a pleiotropic cytokine that binds to the LIFR/gp130
complex of receptors that can signal through the JAK-STAT
pathway (Ernst and Jenkins, 2004). Using a pharmacological
inhibitor of JAK, we have identified the JAK-STAT pathway as
the pathway downstream of the TGF-b-LIF axis required for its
effect on GIC self-renewal. The LIF-JAK-STAT pathway has
been previously implicated in many processes, and depending
on the cellular context, it can regulate the self-renewal capacity
of early neuroprogenitors or induce astrocytic differentiation
(Bauer and Patterson, 2006; Bonni et al., 1997; Molne et al.,
2000; Rajan and McKay, 1998; Wright et al., 2003).
We have discerned the molecular mechanisms involved in the
transcriptional induction of LIF by TGF-b. We have also identified
a functional Smad-binding element on the LIF promoter and
found that an activated Smad complex binds to the proximal
LIF promoter close to an SP1 binding site in order to induce
transcription. LIF induction by TGF-b is a Smad-dependent
process since knockdown of both Smad2 and 3 or Smad4
represses TGF-b-induced LIF expression. Therefore, LIF is
a typical TGF-b-Smad transcriptional response mediated by
a Smad2/3-Smad4 complex.
GICs have functional and molecular similarities to normal neu-
roprogenitors, including their ability to generate neurospheres,
the expression of certain protein markers, and their capability for
multilineage differentiation. However, GICs and normal neuro-
progenitor cells are two different cell types, and comparisons
between them should be made with caution. TGF-b does not
induce the self-renewal capacity of normal human neuroprogeni-
tors obtained from human fetal cerebral cortex samples. LIF, on
the other hand, increases the self-renewal capacity of human
normal neuroprogenitor cells. This is in line with previous reports
showing that LIF induces the self-renewal capacity of human
normal neuroprogenitors and mouse embryonic and adult neuro-
progenitors (Bauer and Patterson, 2006; Molne et al., 2000; Wright
et al., 2003). Interestingly, LIF is not induced by TGF-b in human
normal neuroprogenitors, even though the TGF-b pathway is func-
tional in neuroprogenitors. TGF-b is able to induce p-Smad2 levels
and Smad7 (a well-defined TGF-b target gene) in neuroprogenitors
to the same extent as in GBM neurospheres. Therefore, the lack of
LIF induction in response to TGF-b in normal neuroprogenitors is
dependent on the ability of the Smad transcriptional complex to
specifically bind to the LIF promoter in GICs. Our results demon-
strate that LIF has the same effect on normal neuroprogenitors
and GICs and that the differential response to TGF-b coincides
with the inability of TGF-b to induce LIF in neuroprogenitors.We found that LIF is expressed in human gliomas and
that tumors with high levels of TGF-b2 tend to have high levels
of LIF, indicating that TGF-b2 might be responsible for LIF
expression in human gliomas. Furthermore, high LIF levels
correlate with the expression of markers of neuroprogenitor cells
(Musashi-1 and nestin) in some tumors. This indicates that
tumors expressing high levels of TGF-b2 tend to express high
levels of LIF and are enriched in a cell population expressing
neuroprogenitor markers, corroborating the fact that in human
glioma, the TGF-b2/LIF pathway promotes an increase of the
GIC pool. Interestingly, we observed previously that tumors
with high levels of TGF-b2 tend to be more aggressive (Bruna
et al., 2007). LIF could be one of the mediators of the malignant
behavior of TGF-b2-expressing tumors.
Recently, it has been reported that another member of the
TGF-b family of cytokines, BMP, inhibits GIC self-renewal and
promotes GIC differentiation in GBMs with no epigenetic
silencing of the BMP receptor 1B (BMPR1B) gene (Lee et al.,
2008; Piccirillo et al., 2006). Interestingly, we found that BMP
was not able to induce LIF in glioma cells (data not shown).
This is not the first time that TGF-b and BMP have been reported
to have contrary functions. TGF-b and BMP have opposing
effects on embryonic stem cell self-renewal due in part to their
differential transcriptional regulation of Nanog (Xu et al., 2008).
In epithelial cells, TGF-b transduces its signal through Smad2
and 3 while BMP induces phosphorylation and translocation of
Smad1, 5, and 8 (Massague´ et al., 2005). Hence, the LIF
response to TGF-b and BMP might be dictated by the specific
ability of Smad2/3 and not Smad1/5/8 to be recruited to the
LIF promoter to induce transcription.
TGF-b might have the same effect on tumor-initiating cells of
other tumor types. Interestingly, it has been reported that
a CD44+CD24 cell population in breast tumors, considered to
have stem cell-like properties, have a highly active TGF-b
pathway and are regulated by TGF-b (Mani et al., 2008; Shipitsin
et al., 2007). This suggests that TGF-b may have an important
role in maintaining the stem cell-like pool in breast cancer as
well as in glioma. Further studies are needed to define whether
the molecular mechanisms identified in the present work are
functional in other tumor types.
GICs and tumor-initiating cells in general are critical
therapeutic targets in cancer. An understanding of the exact
mechanisms implicated in the regulation of tumor-initiating cell
self-renewal will provide tools for the development of more
successful therapeutic strategies. Together, our results shed
light on GIC biology and furthermore on the TGF-b oncogenic
response in glioma. The LIF-JAK-STAT pathway increases
human GIC self-renewal, and compounds designed to inhibit
LIF or the JAK-STAT pathway could improve therapeutic strate-
gies against glioma by targeting GICs. Moreover, our data
identify a mechanism through which anti-TGF-b compounds
might be successful against glioma since they will inhibit LIF
expression and decrease GIC self-renewal.
EXPERIMENTAL PROCEDURES
Cell Lines and Primary Cell Cultures
U373MG and A172 cells (a kind gift of J. Rich and D. Bigner) were cultured in
DMEM with 10% fetal bovine serum (FBS). PCTCs and GBM neurospheresCancer Cell 15, 315–327, April 7, 2009 ª2009 Elsevier Inc. 325
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2007). Briefly, tumor samples were processed within 30 min after surgical
resection. Minced pieces of human glioma samples were digested with
200 U/ml collagenase I (Sigma) and 500 U/ml DNase I (Sigma) in PBS for
2 hr at 37C with constant vigorous agitation. The single-cell suspension
was filtered through a 70 mm cell strainer (BD Falcon) and washed with PBS.
Finally, cells were resuspended and subsequently cultured in DMEM with
10% FBS (for PCTC culture) or in neurosphere medium (for GBM neuro-
spheres). Normal human neuroprogenitor neurospheres were generated
from human embryonic cerebral cortex tissue collected following medical
terminations of pregnancy. The samples were processed and cultured as
described previously (Poltavtseva et al., 2002). The neurosphere medium
consisted of Neurobasal medium (GIBCO) supplemented with B27 (GIBCO),
L-glutamine (GIBCO), penicillin/streptomycin, and growth factors (20 ng/ml
EGF and 20 ng/ml FGF-2 [PeproTech]). Human glioma specimens and human
embryonic tissues were obtained from the Vall d’Hebron Hospital. The clinical
protocol was approved by the Vall d’Hebron Institutional Review Board (CEIC),
with informed consent obtained from all subjects.
Intracranial Tumor Assay
All mouse experiments were approved by and performed according to the
guidelines of the Institutional Animal Care Committee of the Vall d’Hebron
Research Institute in agreement with the European Union and national direc-
tives. The indicated number of cells was stereotactically inoculated into the
corpus striatum of the right brain hemisphere (1 mm anterior and 1.8 mm lateral
to the bregma; 2.5 mm intraparenchymal) of 9-week-old NOD/SCID mice
(Charles River Laboratories). Mice were euthanized when they presented
neurological symptoms or a significant loss of weight. Magnetic resonance
imaging (MRI) analysis was performed and images were acquired using
a 9.4 T vertical bore magnet interfaced to an AVANCE 400 system (Bruker).
Under anesthesia by xylazine/ketamine, mice were given an intraperitoneal
injection of gadolinium diethylenetriamine penta-acetic acid at a dose of
0.25 mmol gadolinium/kg body weight and placed in the radio frequency coil
(inner diameter 35 mm). After localizer imaging on three orthogonal axes,
T1-weighted images of the entire mouse brain were acquired using a spin
echo sequence with TR and TE set to 800 and 5.7 ms, respectively. Other
parameters used were a 2.5 cm field of view and a 256 3 256 matrix in two
averages, resulting in a total scan time of approximately 6.5 min. Tumor size
was quantified by measuring the number of pixels corresponding to tumor
tissue in each image using the software provided by the manufacturer (Bruker);
when the tumor was visible in more than one image, areas corresponding to
tumor tissue were quantified together.
Statistical Analysis
A Spearman correlation test was used to analyze relationships between LIF
and TGF-b2, Musashi-1, Sox2, and Nestin. Data in graphs are presented as
mean ± SD.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures, one
table, and seventeen figures and can be found with this article online at
http://www.cancercell.org/supplemental/S1535-6108(09)00042-7.
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